FDA clears repurposed GSK drug for ultra-rare brain disease instead of autism

Months after promising help for “hundreds of thousands of kids,” the FDA approved the decades-old medicine for a disease documented in less than 50 people.

By Kristin Jensen • March 11, 2026

Lilly unveils $3 billion production expansion in China

The Zepbound developer is joining other drugmakers’ rush into China as it plans to boost its oral solid dosage supply chain to support the launch of its obesity pill orforglipron.

By Jonathan Gardner • March 11, 2026

Explore the Trendline➔

Top 5 stories from BioPharma Dive

Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.

By BioPharma Dive staff

Bimzelx tops Skyrizi in head-to-head psoriatic arthritis trial

UCB said it’s the first time an approved biologic demonstrated superiority over an IL-23 blocker in psoriatic arthritis. Yet analysts aren’t sure how commercially impactful the results will be.

By Delilah Alvarado • March 11, 2026

Bristol Myers claims success in study of another next-gen blood cancer drug

The therapy, mezigdomide, is part of group of medicines the pharma sees as successors to its lucrative multiple myeloma drugs Revlimid and Pomalyst.

By Gwendolyn Wu • March 9, 2026

Roche’s prized breast cancer pill fails closely watched study

The result “pulls the rug” out from under giredestrant, according to one analyst, sparking another share selloff following disappointing obesity data last week.

By Jonathan Gardner • March 9, 2026

Rethinking the box: Why circular cold chain packaging is becoming a cost strategy in healthcare

Spend enough time inside a healthcare distribution center and you start to notice something.

March 9, 2026

Roche, Zealand shares fall on ‘undifferentiated’ obesity drug results

An amylin-targeting medicine at the center of the companies’ multibillion-dollar alliance spurred less weight loss than investors had hoped, leading some analysts to question its ability to stand out. 

By Delilah Alvarado • March 6, 2026

Lilly targets employers in new bid to broaden access to obesity drugs

A service tailored to people with workplace-based insurance coverage represents a new way for Lilly to bypass insurers and expand use of its popular obesity shot. 

By Jonathan Gardner • March 5, 2026

Blackstone puts $400M into Teva, Sanofi gut disease drug

The deal adds to a growing biotech presence for Blackstone and supports testing of a drug competing with rival therapies from Merck and Roche.

By Jonathan Gardner • March 4, 2026

Pierre Fabre seeks to revive US approval chances for spurned cell therapy

Ebvallo is one of a series of rare disease treatments recently turned back by the FDA amid shifting guidance that has surprised some companies and frustrated investors.

By Jonathan Gardner • March 3, 2026

Roche pill succeeds in another MS study, but approval questions linger

Liver-related side effects have led some analysts to question fenebrutinib’s prospects, even though the drug has now cleared Phase 3 studies in multiple forms of the disease.

By Jonathan Gardner • March 2, 2026

Lilly’s GLP-1 pill tops Novo’s Rybelsus in head-to-head trial

Orforglipron, which could be approved for obesity next quarter, proved superior at cutting blood sugar and body weight — but at the expense of higher side effect rates. 

By Jonathan Gardner • Feb. 26, 2026

Bristol Myers says ADC licensed from China hits mark in aggressive breast cancer

The study result is the latest step forward for a drug Bristol could eventually pay more than $8 billion for and has spotlighted as important to its future growth.

By Kristin Jensen • Feb. 26, 2026

GSK to acquire 35Pharma in $950M deal for cardiovascular drug

The deal hands GSK a drug it views as a potentially “best-in-class” therapy for blood pressure diseases like pulmonary arterial hypertension — the target of Merck’s fast-selling Winrevair.

By Kristin Jensen • Feb. 25, 2026

With Vivtex deal, Novo gains a chance at better oral obesity drugs

The potentially $2.1 billion collaboration gives Novo access to technologies that are meant to help optimize the delivery of oral biologic medicines. 

By Gwendolyn Wu • Feb. 25, 2026

Novo’s next-gen obesity shot fails to match Lilly drug in head-to-head study

Shares fell by more than 15% on results showing study participants receiving Novo’s CagriSema lost less weight than those who took Lilly’s Zepbound.

By Jonathan Gardner • Feb. 23, 2026

Merck to split cancer, specialty drug businesses in leadership shakeup

Ahead of the looming loss of Keytruda’s exclusivity, the company is creating a standalone, cancer-focused unit and a second business housing its other drugs and vaccines.

By Ben Fidler • Feb. 23, 2026

Small and mighty: single-domain antibodies pack a biological punch

VHH antibodies: they’re not just small, they're modular engineering platforms, capable of powerful biological activity. But with great power comes great challenges!

By Jingyuan Zhang • Feb. 23, 2026

Supreme Court invalidates Trump tariffs based on emergency powers

In a 6-3 decision, the court rejected President Trump's claim that a 1977 law gave him the authority to impose broad tariffs globally.

By Antone Gonsalves • Feb. 20, 2026

Trump sets fresh 10% global tariff — and plans to increase further

The new duties will go into effect Feb. 24, although the president has since signaled he will raise the rate to 15%.

By Antone Gonsalves , Phil Neuffer • Updated Feb. 21, 2026

Roche gets FDA decision date on closely watched breast cancer drug

The agency could by late December approve a therapy that Roche sees as potentially becoming a new treatment standard for certain breast tumors. 

By Jonathan Gardner • Feb. 20, 2026

AI is slashing jobs across industries. Will pharma be next?

Despite a wave of AI-fueled layoffs, the pharma and biotech industries could be spared from massive cutbacks for now.

By Alexandra Pecci • Feb. 20, 2026

Lilly to pay CSL $100M to license monoclonal antibody targeting IL-6

The Australian company will retain rights for an end-stage kidney disease indication currently being tested in a Phase 3 trial while Lilly explores other uses.

By Kristin Jensen • Feb. 18, 2026

FDA accepts BMS protein degrader for review; Disc rare disease drug rejected

Cytokinetics’ heart disease drug secured European approval. Elsewhere, Teva and Sanofi reported longer-term data from an experimental therapy targeting ulcerative colitis and Crohn’s disease.

By BioPharma Dive staff • Feb. 18, 2026

How to evaluate prospective diagnostic laboratory partners for your patient support program

As specialty medicines account for an increasing share of the drug pipeline, it makes sense for sponsors to support patients financially, emotionally and logistically.

Feb. 17, 2026